about
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITTyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adultsAnaplastic lymphoma kinase: signalling in development and diseaseCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewRecent developments in receptor tyrosine kinases targeted anticancer therapyThe Prodrug Approach: A Successful Tool for Improving Drug SolubilityNew Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical TrialsProfile of nintedanib in the treatment of solid tumors: the evidence to dateWithdrawal of anticancer therapy in advanced disease: a systematic literature reviewCross talk of tyrosine kinases with the DNA damage signaling pathwaysProgress toward overcoming hypoxia-induced resistance to solid tumor therapyCardiac effects of anticancer therapy in the elderlyTyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatmentA cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinomaPrecision targeted therapy of ovarian cancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceSteered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and AblNilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasLapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffoldsVEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) miceProperties of protein drug target classesAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionZebrafish Caudal Fin Angiogenesis Assay-Advanced Quantitative Assessment Including 3-Way Correlative MicroscopyHypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural AnalysesEvolving Therapies and FAK Inhibitors for the Treatment of CancerMultikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.kinDOCK: a tool for comparative docking of protein kinase ligands.Natural products active in aberrant c-Kit signaling.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Terrein performs antitumor functions on esophageal cancer cells by inhibiting cell proliferation and synergistic interaction with cisplatin.Angiogenesis inhibition in prostate cancer: current uses and future promises.Inhibition of protein kinases by anticancer DNA intercalator, 4-butylaminopyrimido[4',5':4,5]thieno(2,3-b)quinolineAutologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastasesRevisiting glucose uptake and metabolism in schistosomes: new molecular insights for improved schistosomiasis therapiesSynthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenograftsFibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.Controlling the Mdm2-Mdmx-p53 Circuit.
P2860
Q21142738-F3045776-4877-41C5-95FC-26B8100D11CFQ24187730-6ADE87AA-3B5D-445A-9702-78B2ADF674E9Q24312329-C89B4E9F-D505-4D68-B320-BED46250A370Q26740067-D7DC046B-B5AC-40C3-A84A-D5FD97829C70Q26751331-5D27ACE7-7FDB-4D3B-B2F8-FC8C048E1004Q26771271-780EAD85-F37A-4728-891F-CE27E45EA2FFQ26772800-097645E4-413F-4965-AF06-7F420CF43E55Q26775134-FB3DC60F-8262-4402-9498-DF695121D0D7Q26777486-0682E277-CA95-4112-BF8C-5786FE7518DAQ26778614-46C5C9A8-C466-4572-99AF-BD7256419C53Q26796405-6BC3994E-09E4-462D-A547-AD61427F13BEQ26863244-19C956FC-C0B0-47EC-8F47-AC08100ADCF8Q26998914-262F55E4-535E-4116-9ABA-09802AFD9526Q27307150-0C01A1D7-76CC-49C3-88C4-B296DC30902CQ28078658-C0C0C711-B8D0-4FAF-A195-6E56FAF21FDEQ28079320-D49FE42F-DBE3-478F-A724-F90C9FB0FA20Q28472368-F76DDE63-9B0C-4DA8-B82E-A0BB5779A762Q28483929-E69CB7F7-0873-4B1C-A549-25C825CB72AEQ28486270-D2C862F9-AAF1-4BAA-A0A0-FC6B4A7B746BQ28506974-EA8EA95E-EF3D-4F78-A676-8169A4138005Q28545197-2EE3BE50-90D5-424C-AB29-B9696F0B5275Q28550377-79059F32-7C05-47E4-ADF2-EA0611C90BB5Q28550573-C63B284D-65FC-4577-B647-A41D99E57CDDQ28552577-4A3A7B67-5BEB-42AB-B5B4-EA3688B0D065Q28972291-AED3AF23-AC90-4A42-BE9E-8300F85A2AF2Q30250106-18F0CE68-95A7-4C83-803A-49234D873516Q33250339-E2F881CB-0B37-41FB-9C09-908E4756071EQ33286316-B7C74ED5-A450-47A4-906B-9CA60C60504AQ33410375-406A3B54-6665-4A15-AE0A-A6A066AEBCCAQ33599051-6891BE16-122B-49A8-9651-68CAF1A6B75EQ33652297-3FEFF890-1EAF-4D99-9E4B-B6A077135AA0Q33682972-BA2F2C79-5F1C-4891-90C4-5DB90606B460Q33713800-2D749298-4A68-4F15-882B-648B30A3F6ABQ33735929-33E91BE3-E92F-4E27-B0F0-4F271496DC61Q33847057-F2107043-5D49-4358-8AAD-73DA301F2940Q33888789-1D1431D6-BE06-483C-BE0A-5B8002A5B04BQ33890597-5B6C3CD1-11A2-4F57-84AF-0B3270190286Q33918198-F37AB0D8-0533-4E6A-A04A-EDAEA0D38BFCQ33977104-4314A59C-7C58-4237-B2A5-266063355168Q34011009-B2D0E409-DFDD-4C74-B020-48DE08126CEF
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Role of tyrosine kinase inhibitors in cancer therapy.
@ast
Role of tyrosine kinase inhibitors in cancer therapy.
@en
Role of tyrosine kinase inhibitors in cancer therapy.
@nl
type
label
Role of tyrosine kinase inhibitors in cancer therapy.
@ast
Role of tyrosine kinase inhibitors in cancer therapy.
@en
Role of tyrosine kinase inhibitors in cancer therapy.
@nl
prefLabel
Role of tyrosine kinase inhibitors in cancer therapy.
@ast
Role of tyrosine kinase inhibitors in cancer therapy.
@en
Role of tyrosine kinase inhibitors in cancer therapy.
@nl
P356
P1476
Role of tyrosine kinase inhibitors in cancer therapy.
@en
P2093
Amit Arora
Eric M Scholar
P304
P356
10.1124/JPET.105.084145
P407
P577
2005-07-07T00:00:00Z